Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Maltais (Quebec, Canada), C. Vogelmeier (Marburg, Germany), I. Boucot (Brentford, Middlesex, United Kingdom), L. Bjermer (Lund, Sweden), E. Kerwin (Medford, OR, United States of America), I. Naya (Brentford, Middlesex, United Kingdom), L. Tombs (Brentford, Middlesex, United Kingdom), C. Compton (Brentford, Middlesex, United Kingdom), D. Lipson (Collegeville and Philadelphia, PA, United States of America), P. Jones (Brentford, Middlesex, United Kingdom). Improving COPD symptoms with umeclidinium/vilanterol and impact of baseline disease severity: the EMAX trial. 2473

Member's Comments

No comment yet.

Related content which might interest you: Umeclidinium/vilanterol in preventing clinically important deterioration (CID) in COPD and impact of baseline disease severity: the EMAX trial Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Improving daily COPD symptoms, as measured using the E-RS, with umeclidinium/vilanterol versus monotherapy: the EMAX trial Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) Source: Annual Congress 2005 - Systemic effects of COPD Year: 2005 Patient-reported outcomes (PROs) and reliever use in Japanese and European patients with chronic obstructive pulmonary disease receiving formoterol 4.5 and 9μg twice daily: Results of the OCEAN phase III study Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010 Baseline symptom scores and future risk of severe exacerbation: The SPARK study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Once-daily QVA149 improves symptom scores in patients with COPD Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 LATE-BREAKING ABSTRACT: Intra-day symptoms fluctuations: STORICO, observational study on the characterization of 24-hour symptoms in COPD patients Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 Once-daily QVA149 has a good safety profile in patients with COPD Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Acute exacerbation phenotypes of asthma and COPD: impact on clinical outcomes Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations Year: 2021 A pilot study to assess the efficacy of breathlessness plans for patients with chronic obstructive pulmonary disease (COPD) Source: International Congress 2016 – COPD diagnosis and management Year: 2016 QVA149 provides significant symptomatic benefit to COPD patients as measured by a new symptom e-diary: The SHINE study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Comparisons among various QOL assessments and clinical outcomes for one year in elderly patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2004; 24: Suppl. 48, 66s Year: 2004 A randomised controlled trial of cognitive behavioural therapy (CBT) delivered by respiratory nurses to reduce anxiety in chronic obstructive pulmonary disease (COPD). (Trial registration - ISCRCTN55206395) Source: International Congress 2016 – Respiratory nursing research: opening new perspectives on patient experiences Year: 2016